104 related articles for article (PubMed ID: 15500435)
1. Development of glycoprotein IIb-IIIa antagonists: translation of pharmacodynamic effects into clinical benefit.
Schneider DJ; Aggarwal A
Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):903-13. PubMed ID: 15500435
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
Keating FK; Whitaker DA; Sobel BE; Schneider DJ
Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
[TBL] [Abstract][Full Text] [Related]
3. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
Sirotkina OV; Khaspekova SG; Zabotina AM; Shimanova YV; Mazurov AV
Platelets; 2007 Nov; 18(7):506-14. PubMed ID: 17957566
[TBL] [Abstract][Full Text] [Related]
4. Current strategies with high-dose tirofiban.
Mukherjee D; Roffi M
Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):275-80. PubMed ID: 17428156
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
6. Measurement of glycoprotein IIb/IIIa blockade by flow cytometry with fluorescein isothiocyanate-conjugated crotavirin, a member of disintegrins.
Liu CZ; Hur BT; Huang TF
Thromb Haemost; 1996 Oct; 76(4):585-91. PubMed ID: 8903000
[TBL] [Abstract][Full Text] [Related]
7. Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen.
Schneider DJ; Baumann PQ; Whitaker DA; Sobel BE
J Cardiovasc Pharmacol; 2005 Jul; 46(1):41-5. PubMed ID: 15965353
[TBL] [Abstract][Full Text] [Related]
8. The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients.
Tricoci P; Peterson ED
J Interv Cardiol; 2006 Oct; 19(5):449-55. PubMed ID: 17020570
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.
Li YF; Spencer FA; Becker RC
Am Heart J; 2002 Apr; 143(4):725-32. PubMed ID: 11923812
[TBL] [Abstract][Full Text] [Related]
10. Increased ability of tirofiban to maintain its inhibitory effects on the binding of fibrinogen to platelets in blood from patients with and without diabetes mellitus.
Schneider DJ; Keating FK; Baumann PQ; Whitaker DA; Sobel BE
Coron Artery Dis; 2006 Feb; 17(1):57-61. PubMed ID: 16374143
[TBL] [Abstract][Full Text] [Related]
11. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
Harrington RA
Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
[TBL] [Abstract][Full Text] [Related]
12. Off-target effects of glycoprotein IIb/IIIa receptor inhibitors.
Ostrowska M; Adamski P; Koziński M; Navarese EP; Fabiszak T; Grześk G; Paciorek P; Kubica J
Cardiol J; 2014; 21(5):458-64. PubMed ID: 24526503
[TBL] [Abstract][Full Text] [Related]
13. Platelet glycoprotein IIb/IIIa inhibition and its clinical use.
Huang F; Hong E
Curr Med Chem Cardiovasc Hematol Agents; 2004 Jul; 2(3):187-96. PubMed ID: 15320785
[TBL] [Abstract][Full Text] [Related]
14. Coronary intervention and glycoprotein IIb/IIIa integrin blockade.
Madan M; Tcheng JE
Coron Artery Dis; 1999 Dec; 10(8):553-60. PubMed ID: 10599533
[TBL] [Abstract][Full Text] [Related]
15. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes.
Maree A; Fitzgerald D
Haematologica; 2001 Nov; 86(11 Suppl 2):45-8. PubMed ID: 11926777
[No Abstract] [Full Text] [Related]
16. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.
Lele M; Sajid M; Wajih N; Stouffer GA
Circulation; 2001 Jul; 104(5):582-7. PubMed ID: 11479257
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacology of GP IIb/IIIa antagonists.
Schrör K; Weber AA
J Thromb Thrombolysis; 2003 Apr; 15(2):71-80. PubMed ID: 14618072
[TBL] [Abstract][Full Text] [Related]
18. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: where are we now?
Maree A; Fitzgerald DJ
Semin Vasc Med; 2003 Nov; 3(4):385-90. PubMed ID: 15199445
[TBL] [Abstract][Full Text] [Related]
19. Use of GPIIb/IIIa inhibitors in cardiovascular medicine.
Ahrens I; Peter K; Bode C
Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):233-42. PubMed ID: 15030283
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of platelets glycoprotein IIb/IIIa (GP IIb/IIIa) receptor: rationale for their use in clinical cardiology.
Rossi ML; Zavalloni D
Mini Rev Med Chem; 2004 Sep; 4(7):703-9. PubMed ID: 15379638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
